CJC
CJC-1295
A synthetic analogue of the first 29 residues of growth-hormone-releasing hormone, carrying four substitutions — D-alanine at 2, glutamine at 8, alanine at 15 and leucine at 27 — each of which blocks a known site of enzymatic cleavage. It binds the GHRH receptor. A separate version carrying a maleimidopropionic acid group that binds albumin is a different substance, and the two are frequently sold under the same name.
CJC-1295 has 1 registered human study on ClinicalTrials.gov, reaching phase 2, covering 120 planned or enrolled participants across the 1 study that published a figure. No FDA-approved product contains CJC-1295. 18 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names CJC-1295; the registry search is fuzzy, so every match is re-checked. None of this says whether CJC-1295 works or is safe.
FDA status
Research only
Human studies
1
Furthest phase
Phase 2
Papers, 10 yr
18
Readership
10,462
monthly average, Feb–Jun 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Phase 1 or 2 only
1
Registered human studies
Phase 2
Furthest phase reached
120
Planned or enrolled participants, across 1 study that published a figure
None
No FDA-approved product contains it
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What CJC-1295 is, and what it has been studied for
CJC-1295 is tracked here. Its FDA substance identifier is 62RC32V9N7.
Across 1 registered trial, it has been studied in Obesity and HIV Infections. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by ConjuChem. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
CJC-1295 reached Phase 2 across 1 registered trial.
No FDA-approved product contains CJC-1295. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying CJC-1295?
Papers published each year that name CJC-1295 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 1 | 0 | Yes |
| 2019 | 2 | 0 | Yes |
| 2020 | 1 | 0 | Yes |
| 2021 | 2 | 0 | Yes |
| 2022 | 3 | 0 | Yes |
| 2023 | 1 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 1 | 0 | Yes |
| 2026 | 9 | 0 | No |
18 papers between 2017 and 2026. A paper counts when “CJC-1295” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on CJC-1295
18 indexed papers name CJC-1295 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS
- Advances in the detection of growth hormone releasing hormone synthetic analogs
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
Collected 2026-08-02from PubMed, phrase-matched on “CJC-1295” in title and abstract. Run the same search.
About CJC-1295
A synthetic analogue of the first 29 residues of growth-hormone-releasing hormone, carrying four substitutions — D-alanine at 2, glutamine at 8, alanine at 15 and leucine at 27 — each of which blocks a known site of enzymatic cleavage. It binds the GHRH receptor. A separate version carrying a maleimidopropionic acid group that binds albumin is a different substance, and the two are frequently sold under the same name.
- Also known as
- Modified GRF (1-29) · CJC1295
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.